secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001193125-22-307328
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix amends bylaws to comply with new universal proxy rules and DGCL updates
-----------------------------------------------------------------------------

- Revised advance notice bylaws require additional disclosures from nominating stockholders and restrict number of nominees to directors up for election.
- Added compliance requirements for stockholders using universal proxy rules (Rule 14a-19), including certification and evidence submission 5 business days before meeting.
- Updated meeting conduct: presiding officer may set extra attendance procedures; proxy card color must be non-white for soliciting stockholders.
- Added emergency bylaw provision to allow board or committee quorum during situations preventing normal meeting requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522307328/0001193125-22-307328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522307328/d410964d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-307328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer